Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sysmex and bioMerieux form joint venture in Japan
The new company, called Sysmex bioMerieux will promote and commercialize the entire bioMerieux product range in Japan starting April 1, 2008. The joint venture (JV) will manage the
The new company, called Sysmex bioMerieux will promote and commercialize the entire bioMerieux product range in Japan starting April 1, 2008. The joint venture (JV) will manage the
Under the terms of the agreement, valued at up to $35 million, Celtic will take an equity stake in Inspiration as well as provide clinical development expertise and
Proceeds from the financing will be used to support the commercialization of sumatriptan DosePro for which the company submitted a new drug application (NDA) with the FDA in
The agreement enables Surgical Express (SRI) to offer its full line of reprocessing services to Premier alliance members. Premier’s more than 1,500 member hospitals and 47,000 other healthcare
In this trial, patients will receive 75mg/m2 of Vidaza (azacitidine for injection) either intravenously or subcutaneously in combination with an oral dose of MGCD0103 in 28-day cycles. Key
Oxcarbazepine tablets, marketed by Novartis as Trileptal tablets, are prescription pharmaceutical products used in treating seizures. Taro has recently settled litigation with Novartis regarding Taro’s ‘Paragraph IV’ certification
The debenture bears an interest rate of 8% and is convertible into common shares at $0.20 per share, as long as the company meets certain milestones. YA cannot
Proteologics has anti-viral drug discovery programs based on proprietary research of host-protein ubiquitin-ligase drug targets shown to be essential for the HIV life cycle. Proteologics strategy is to
The acquisition is expected to add more than $55 million in sales annually and be accretive to earnings in the first year. Joseph Papa, chairman and CEO of
The company said that this is the first issuance from a series of patent applications covering its XmAb antibody Fc engineering technology, which is comprised of a suite